{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T18:51:25Z","timestamp":1784055085420,"version":"3.55.0"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.critrevonc.2026.105158","type":"journal-article","created":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T00:35:53Z","timestamp":1769560553000},"page":"105158","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Trastuzumab deruxtecan in non-breast solid tumors: Expanding indications, efficacy, and future directions"],"prefix":"10.1016","volume":"220","author":[{"given":"A.","family":"Ghidini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Bukovec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Roncari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Dottorini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Petrelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"15","key":"10.1016\/j.critrevonc.2026.105158_bib1","first-page":"1276","article-title":"Trastuzumab in combination with chemotherapy versus chemotherapy alone for HER2-positive advanced gastric cancer (ToGA)","volume":"362","author":"Bang","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105158_bib2","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1200\/JCO.2016.69.4836","article-title":"HER2 testing and clinical decision making in gastroesophageal adenocarcinoma: guideline from the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology","volume":"35","author":"Bartley","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105158_bib3","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1339302","article-title":"ERBB2 (HER2) amplifications and co-occurring KRAS alterations in the circulating cell-free DNA of pancreatic ductal adenocarcinoma patients and response to HER2 inhibition","volume":"14","author":"Barzi","year":"2024","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105158_bib4","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.693394","article-title":"HER2 positivity in histological subtypes of salivary gland carcinoma: a systematic review and meta-analysis","volume":"11","author":"Egebjerg","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105158_bib5","unstructured":"European Medicines Agency (EMA). Enhertu (trastuzumab deruxtecan): extension of indication for HER2-mutant NSCLC. Published 2023. Accessed August 24, 2025. \u3008https:\/\/www.ema.europa.eu\u3009."},{"key":"10.1016\/j.critrevonc.2026.105158_bib6","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.70078","article-title":"Analytical and clinical validation of a next-generation sequencing panel for detecting targetable variants from circulating tumor DNA of metastatic non\u2013small cell lung cancer patients","volume":"13","author":"Fan","year":"2024","journal-title":"Cancer Med."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105158_bib7","first-page":"519","article-title":"Trastuzumab deruxtecan in patients with HER2-mutant metastatic non\u2013small-cell lung cancer (DESTINY-Lung02)","volume":"24","author":"Goto","year":"2023","journal-title":"Lancet Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105158_bib8","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1200\/JCO.2015.62.6598","article-title":"Lapatinib in combination with capecitabine plus oxaliplatin in human epidermal growth factor receptor 2-positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma: TRIO-013\/LOGiC\u2014A randomized phase III trial","volume":"34","author":"Hecht","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105158_bib9","first-page":"201","article-title":"Trastuzumab deruxtecan in Western patients with HER2-positive gastric or gastroesophageal junction cancer (DESTINY-Gastric02)","volume":"23","author":"Kang","year":"2022","journal-title":"Lancet Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105158_bib10","doi-asserted-by":"crossref","first-page":"S613","DOI":"10.1016\/j.annonc.2024.08.909","article-title":"Phase II study of trastuzumab deruxtecan in patients with HER2-positive recurrent\/metastatic salivary gland cancer: results from the MYTHOS trial","volume":"35","author":"Kinoshita","year":"2024","journal-title":"Ann. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105158_bib11","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMoa2112431","article-title":"Trastuzumab deruxtecan in HER2-mutant non\u2013small-cell lung cancer","volume":"387","author":"Li","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105158_bib12","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1111\/bju.15006","article-title":"Urothelial cancer harbours EGFR and HER2 amplifications and exon 20 insertions","volume":"125","author":"Madison","year":"2020","journal-title":"BJU Int."},{"key":"10.1016\/j.critrevonc.2026.105158_bib13","first-page":"1205","article-title":"Trastuzumab deruxtecan in patients with HER2-expressing advanced endometrial cancer: results from the DESTINY-PanTumor02 study","volume":"29","author":"Makker","year":"2023","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105158_bib14","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/s41523-024-00621-x","article-title":"Digital PCR quantification of ultrahigh ERBB2 copy number identifies poor breast cancer survival after trastuzumab","volume":"10","author":"Meng","year":"2024","journal-title":"NPJ Breast Cancer"},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105158_bib15","first-page":"2688","article-title":"HER2 as a pan-cancer target and trial designs for tissue-agnostic development","volume":"27","author":"Meric-Bernstam","year":"2021","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105158_bib16","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial","volume":"42","author":"Meric-Bernstam","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"14","key":"10.1016\/j.critrevonc.2026.105158_bib17","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.1158\/1078-0432.CCR-24-2763","article-title":"ctDNA analysis in ERBB2-amplified colorectal cancer: biomarker analysis of the MyPathway trial","volume":"31","author":"Meric-Bernstam","year":"2025","journal-title":"Clin. Cancer Res."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105158_bib18","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1056\/NEJMoa1914510","article-title":"Trastuzumab deruxtecan in previously treated HER2-positive breast cancer","volume":"382","author":"Modi","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105158_bib19","unstructured":"National Comprehensive Cancer Network (NCCN). NCCN Guidelines: Gastric and Esophageal Cancers. Version 2024. Accessed August 24, 2025b. \u3008https:\/\/www.nccn.org\u3009."},{"key":"10.1016\/j.critrevonc.2026.105158_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2023.107385","article-title":"Management of HER2 alterations in non\u2013small cell lung cancer: the past, present, and future","volume":"186","author":"Nutzinger","year":"2023","journal-title":"Lung Cancer"},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105158_bib21","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1111\/cas.12966","article-title":"Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity","volume":"107","author":"Ogitani","year":"2016","journal-title":"Cancer Sci."},{"key":"10.1016\/j.critrevonc.2026.105158_bib22","article-title":"Multicenter prospective EN-MARK study: efficacy of third-line trastuzumab deruxtecan and dynamic changes in biomarkers, including HER2 status","volume":"10","author":"Ooki","year":"2025","journal-title":"ESMO Gastrointest. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105158_bib23","doi-asserted-by":"crossref","DOI":"10.1177\/17588359251367344","article-title":"Clinical relevance of circulating tumor DNA in HER2-positive advanced gastric cancer: a collaborative study of a phase Ib trial of dual HER2 and PD-1 targeted therapy (Ni-High)","volume":"17","author":"Osumi","year":"2025","journal-title":"Ther. Adv. Med Oncol."},{"key":"10.1016\/j.critrevonc.2026.105158_bib24","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ejca.2015.09.018","article-title":"Extra-gain of HER2-positive cases through HER2 reassessment in primary and metastatic sites in advanced gastric cancer with initially HER2-negative primary tumours: Results of GASTric cancer HER2 reassessment study 1 (GASTHER1)","volume":"53","author":"Park","year":"2016","journal-title":"Eur. J. Cancer"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105158_bib25","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/ajco.12653","article-title":"Human epidermal growth factor receptor 2 status of gastric cancer patients in Asia: results from a large, multicountry study","volume":"13","author":"Pathmanathan","year":"2017","journal-title":"Asia Pac. J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105158_bib26","unstructured":"Pharmaceuticals and Medical Devices Agency (PMDA), Japan. Enhertu approval for HER2-positive gastric cancer. Published 2020. Accessed August 24, 2025. \u3008https:\/\/www.pmda.go.jp\u3009."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105158_bib27","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1002\/ijc.30408","article-title":"HER2 loss in HER2-positive gastric or gastroesophageal cancer after trastuzumab therapy: implication for further clinical research","volume":"139","author":"Pietrantonio","year":"2016","journal-title":"Int J. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105158_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2025.102284","article-title":"Disitamab vedotin in preclinical models of HER2-positive breast and gastric cancers resistant to trastuzumab emtansine and trastuzumab deruxtecan","volume":"53","author":"Pourjamal","year":"2025","journal-title":"Transl. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105158_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100554","article-title":"Pooled analysis of drug-related interstitial lung disease and\/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies","volume":"7","author":"Powell","year":"2022","journal-title":"ESMO Open"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105158_bib30","article-title":"Consensus for HER2 alterations testing in non\u2013small-cell lung cancer","volume":"7","author":"Ren","year":"2022","journal-title":"ESMO Open"},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105158_bib31","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1634\/theoncologist.2008-0230","article-title":"The HER-2 receptor and breast cancer: ten years of targeted anti\u2013HER-2 therapy and personalized medicine","volume":"14","author":"Ross","year":"2009","journal-title":"Oncologist"},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105158_bib32","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/modpathol.2011.198","article-title":"HER2 testing in gastric cancer: a practical approach","volume":"25","author":"R\u00fcschoff","year":"2012","journal-title":"Mod. Pathol."},{"issue":"19","key":"10.1016\/j.critrevonc.2026.105158_bib33","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1200\/JCO.2013.53.6136","article-title":"Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN\u2014A randomized phase III study","volume":"32","author":"Satoh","year":"2014","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105158_bib34","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s10120-018-0891-1","article-title":"Loss of HER2 positivity after anti-HER2 chemotherapy in HER2-positive gastric cancer patients: results of the GASTric cancer HER2 reassessment study 3 (GASTHER3)","volume":"22","author":"Seo","year":"2019","journal-title":"Gastric Cancer"},{"issue":"16","key":"10.1016\/j.critrevonc.2026.105158_bib35","article-title":"Linker-cleavable enzymes determine anti-tumor activity of trastuzumab deruxtecan in HER2-positive lung cancer and HER2-low breast cancer","volume":"85","author":"Shiraishi","year":"2025","journal-title":"Cancer Res."},{"issue":"25","key":"10.1016\/j.critrevonc.2026.105158_bib36","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa2004413","article-title":"Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer (DESTINY-Gastric01)","volume":"382","author":"Shitara","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105158_bib37","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S1470-2045(21)00086-3","article-title":"Trastuzumab deruxtecan (T-DXd) in patients with HER2-expressing metastatic colorectal cancer: DESTINY-CRC01","volume":"22","author":"Siena","year":"2021","journal-title":"Lancet Oncol."},{"issue":"4785","key":"10.1016\/j.critrevonc.2026.105158_bib38","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1126\/science.3798106","article-title":"Human breast cancer: correlation of relapse and survival with amplification of the HER2\/neu oncogene","volume":"235","author":"Slamon","year":"1987","journal-title":"Science"},{"issue":"4905","key":"10.1016\/j.critrevonc.2026.105158_bib39","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1126\/science.2470152","article-title":"Studies of the HER-2\/neu proto-oncogene in human breast and ovarian cancer","volume":"244","author":"Slamon","year":"1989","journal-title":"Science"},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105158_bib40","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2","volume":"344","author":"Slamon","year":"2001","journal-title":"N. Engl. J. Med"},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105158_bib41","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/S1470-2045(17)30111-0","article-title":"Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomized, open-label, adaptive phase 2\/3 study","volume":"18","author":"Thuss-Patience","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2026.105158_bib42","article-title":"Trastuzumab deruxtecan plus pertuzumab for HER2-positive metastatic breast cancer","author":"Tolaney","year":"2025","journal-title":"N. Engl. J. Med"},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105158_bib43","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1158\/2159-8290.CD-19-1014","article-title":"Targeting HER2 with trastuzumab deruxtecan: a dose-expansion, phase I study in multiple advanced solid tumors","volume":"10","author":"Tsurutani","year":"2020","journal-title":"Cancer Discov."},{"key":"10.1016\/j.critrevonc.2026.105158_bib44","unstructured":"U.S. Food and Drug Administration (FDA). FDA approves fam-trastuzumab deruxtecan-nxki for unresectable or metastatic HER2-mutant NSCLC. Published August 11, 2022. Accessed August 24, 2025a. https:\/\/www.fda.gov."},{"key":"10.1016\/j.critrevonc.2026.105158_bib45","unstructured":"U.S. Food and Drug Administration (FDA). FDA approves fam-trastuzumab deruxtecan-nxki for HER2-positive gastric\/GEJ adenocarcinoma. Published January 15, 2021. Accessed August 24, 2025a. \u3008https:\/\/www.fda.gov\u3009 ."},{"key":"10.1016\/j.critrevonc.2026.105158_bib46","unstructured":"U.S. Food and Drug Administration (FDA). FDA grants tissue-agnostic approval to fam-trastuzumab deruxtecan-nxki for HER2-overexpressing solid tumors. Published April 5, 2024. Accessed August 24, 2025b. \u3008https:\/\/www.fda.gov\u3009 ."},{"key":"10.1016\/j.critrevonc.2026.105158_bib47","unstructured":"U.S. Food and Drug Administration (FDA). FDA approves fam-trastuzumab deruxtecan-nxki with pertuzumab for unresectable or metastatic HER2-positive breast cancer. Published December 15, 2025. Accessed January 7, 2026."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105158_bib48","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1093\/annonc\/mdw235","article-title":"ESMO consensus guidelines for the management of patients with metastatic colorectal cancer","volume":"27","author":"Van Cutsem","year":"2016","journal-title":"Ann. Oncol."},{"issue":"19","key":"10.1016\/j.critrevonc.2026.105158_bib49","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","article-title":"Trastuzumab emtansine for HER2-positive advanced breast cancer","volume":"367","author":"Verma","year":"2012","journal-title":"N. Engl. J. Med"},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105158_bib50","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1007\/s00535-018-1464-0","article-title":"Clinical impact of intratumoral HER2 heterogeneity on trastuzumab efficacy in patients with HER2-positive gastric cancer","volume":"53","author":"Wakatsuki","year":"2018","journal-title":"J. Gastroenterol."},{"key":"10.1016\/j.critrevonc.2026.105158_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2025.217900","article-title":"Drug-tolerant persisting polyploid giant cancer cells mediate resistance to HER2-targeting antibody-drug conjugates","volume":"630","author":"Yazdi","year":"2025","journal-title":"Cancer Lett."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105158_bib52","doi-asserted-by":"crossref","first-page":"765","DOI":"10.4143\/crt.2023.1294","article-title":"Analytical and clinical validation of a highly sensitive NGS-based circulating tumor DNA assay with real-world concordance in non\u2013small cell lung cancer","volume":"56","author":"Yi","year":"2024","journal-title":"Cancer Res Treat."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105158_bib53","first-page":"121","article-title":"HER2-targeted therapies beyond breast cancer: an update","volume":"21","author":"Yoon","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105158_bib54","first-page":"221","article-title":"Phase II study of trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer: DESTINY-CRC02","volume":"42","author":"Yoshino","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105158_bib55","first-page":"58","article-title":"Targeting HER2 genomic alterations in non\u2013small-cell lung cancer","volume":"1","author":"Zeng","year":"2021","journal-title":"J. Natl. Cancer Cent."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105158_bib56","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.flm.2018.11.002","article-title":"Using digital PCR to detect HER2 amplification in breast and gastric cancer patients","volume":"2","author":"Zhou","year":"2018","journal-title":"Front Lab Med"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826000454?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826000454?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T19:58:10Z","timestamp":1776974290000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842826000454"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":56,"alternative-id":["S1040842826000454"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105158","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Trastuzumab deruxtecan in non-breast solid tumors: Expanding indications, efficacy, and future directions","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105158","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105158"}}